Lantheus (LNTH) Competitors $70.57 -0.62 (-0.87%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$70.74 +0.17 (+0.23%) As of 08/1/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock LNTH vs. SMMT, INSM, TEVA, GMAB, RDY, MRNA, QGEN, VTRS, ASND, and VRNAShould you be buying Lantheus stock or one of its competitors? The main competitors of Lantheus include Summit Therapeutics (SMMT), Insmed (INSM), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Moderna (MRNA), Qiagen (QGEN), Viatris (VTRS), Ascendis Pharma A/S (ASND), and Verona Pharma PLC American Depositary Share (VRNA). These companies are all part of the "pharmaceutical products" industry. Lantheus vs. Its Competitors Summit Therapeutics Insmed Teva Pharmaceutical Industries Genmab A/S Dr. Reddy's Laboratories Moderna Qiagen Viatris Ascendis Pharma A/S Verona Pharma PLC American Depositary Share Lantheus (NASDAQ:LNTH) and Summit Therapeutics (NASDAQ:SMMT) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, risk, earnings, valuation, media sentiment and analyst recommendations. Is LNTH or SMMT more profitable? Lantheus has a net margin of 16.55% compared to Summit Therapeutics' net margin of 0.00%. Lantheus' return on equity of 36.99% beat Summit Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Lantheus16.55% 36.99% 20.55% Summit Therapeutics N/A -62.87%-51.61% Do institutionals & insiders hold more shares of LNTH or SMMT? 99.1% of Lantheus shares are held by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are held by institutional investors. 1.5% of Lantheus shares are held by insiders. Comparatively, 84.9% of Summit Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Does the media favor LNTH or SMMT? In the previous week, Lantheus had 13 more articles in the media than Summit Therapeutics. MarketBeat recorded 20 mentions for Lantheus and 7 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 0.97 beat Lantheus' score of 0.91 indicating that Summit Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantheus 13 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Summit Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend LNTH or SMMT? Lantheus currently has a consensus price target of $131.20, suggesting a potential upside of 85.91%. Summit Therapeutics has a consensus price target of $34.67, suggesting a potential upside of 28.06%. Given Lantheus' stronger consensus rating and higher probable upside, analysts plainly believe Lantheus is more favorable than Summit Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lantheus 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83Summit Therapeutics 2 Sell rating(s) 0 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 2.79 Which has higher earnings & valuation, LNTH or SMMT? Lantheus has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLantheus$1.53B3.18$312.44M$3.5220.05Summit TherapeuticsN/AN/A-$221.32M-$0.34-79.62 Which has more risk and volatility, LNTH or SMMT? Lantheus has a beta of 0.14, indicating that its stock price is 86% less volatile than the S&P 500. Comparatively, Summit Therapeutics has a beta of -1.01, indicating that its stock price is 201% less volatile than the S&P 500. SummaryLantheus beats Summit Therapeutics on 12 of the 16 factors compared between the two stocks. Get Lantheus News Delivered to You Automatically Sign up to receive the latest news and ratings for LNTH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LNTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LNTH vs. The Competition Export to ExcelMetricLantheusMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.93B$10.40B$5.48B$9.51BDividend YieldN/A1.99%4.73%4.08%P/E Ratio20.0518.4228.6723.80Price / Sales3.1829.01373.9066.65Price / Cash10.0322.3135.4557.96Price / Book4.513.478.275.55Net Income$312.44M$234.77M$3.24B$259.03M7 Day Performance-3.24%-4.82%-3.69%-4.59%1 Month Performance-11.37%1.80%4.33%4.46%1 Year Performance-27.69%-12.51%25.95%18.03% Lantheus Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LNTHLantheus4.6193 of 5 stars$70.57-0.9%$131.20+85.9%-28.4%$4.93B$1.53B20.05700News CoverageUpcoming EarningsAnalyst RevisionSMMTSummit Therapeutics2.8961 of 5 stars$26.34+0.5%$34.67+31.6%+153.9%$19.56B$700K-77.47110Upcoming EarningsINSMInsmed3.784 of 5 stars$102.78+0.2%$108.47+5.5%+44.3%$19.50B$363.71M-17.271,271Positive NewsUpcoming EarningsTEVATeva Pharmaceutical Industries3.9815 of 5 stars$16.30+1.5%$24.71+51.7%-12.3%$18.69B$16.54B-14.1736,830News CoveragePositive NewsEarnings ReportGMABGenmab A/S3.6799 of 5 stars$21.69-0.9%$37.80+74.3%-23.2%$13.92B$3.12B12.322,682News CoverageUpcoming EarningsShort Interest ↑RDYDr. Reddy's Laboratories1.9721 of 5 stars$14.57+0.6%$16.95+16.4%-15.5%$12.16B$3.81B22.0727,811MRNAModerna4.4709 of 5 stars$30.97-0.9%$46.61+50.5%-70.7%$11.98B$3.24B-3.555,800Trending NewsEarnings ReportAnalyst ForecastOptions VolumeGap DownQGENQiagen3.3183 of 5 stars$48.06-0.6%$49.40+2.8%+12.1%$10.68B$1.98B120.495,765News CoverageUpcoming EarningsVTRSViatris2.2182 of 5 stars$8.90+0.2%$10.40+16.9%-26.3%$10.45B$14.74B-2.8132,000Upcoming EarningsShort Interest ↑ASNDAscendis Pharma A/S3.0931 of 5 stars$168.02-1.1%$223.07+32.8%+27.8%$10.27B$393.54M-26.751,017Analyst ForecastVRNAVerona Pharma PLC American Depositary Share2.1954 of 5 stars$104.90flat$109.00+3.9%+365.2%$8.93B$42.28M-52.4530Positive NewsUpcoming EarningsShort Interest ↑ Related Companies and Tools Related Companies SMMT Competitors INSM Competitors TEVA Competitors GMAB Competitors RDY Competitors MRNA Competitors QGEN Competitors VTRS Competitors ASND Competitors VRNA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LNTH) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lantheus Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lantheus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
